Predict your next investment

Bd Biosciences company logo
Corporation
HEALTHCARE | Medical Devices & Equipment / Imaging & Diagnostic Equipment
bdbiosciences.com

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

Partners & Customers

10

About Bd Biosciences

Bd Biosciences is a medical device company. It had developed the Bd Multitest 6-color Tbnk Reagent, Model 644611.BD Biosciences is a world leader in bringing innovative diagnostic and research tools to life scientists, clinical researchers, laboratory professionals, and clinicians who are involved in basic research, drug discovery and development, biopharmaceutical production, and disease management.

Bd Biosciences Headquarter Location

2350 Qume Dr.

San Jose, California, 95131,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bd Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Bd Biosciences in 2 Expert Collections, including Conference Exhibitors.

C

Conference Exhibitors

5,302 items

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Bd Biosciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Bd Biosciences Rank

Latest Bd Biosciences News

06:50 ET BD Selects Torrey View by Breakthrough as San Diego Campus for Growing Biosciences Business

Nov 22, 2021

Breakthrough Properties secures first major prelease for 10-acre life science development within one year after land acquisition Torrey View project responds to growing demand for superior scientific research and development space in one of the nation's fastest growing life sciences markets BD Biosciences campus to cultivate innovation and increase speed to market for critical research and clinical reagents News provided by Share this article Share this article SAN DIEGO, Nov. 22, 2021 /PRNewswire/ -- Breakthrough Properties , a leading global developer of life sciences real estate, formed through a joint venture of Tishman Speyer and Bellco Capital, today announced that leading global medical technology company BD (Becton, Dickinson and Company) has selected Torrey View by Breakthrough as home for an expanded San Diego Reagent Innovation Center for its growing BD Biosciences business. Torrey View by Breakthrough - Image Courtesy of Breakthrough Properties Torrey View by Breakthrough – Image Courtesy of Breakthrough Properties "We are thrilled to welcome BD Biosciences to Torrey View and the broader Breakthrough family," said Susie Harborth, Executive Vice President for Operations at Breakthrough Properties. "BD is exactly the type of dynamic and fast-growing firm we had in mind when we set out to create this life science campus. We are honored and proud to support a company that plays such a critical role in advancing the world of health." Puneet Sarin, Worldwide President for BD Biosciences, said, "Our new facility in San Diego will aid in elevating our research, development and operations capabilities and position BD for exciting growth. BD Biosciences is a cornerstone of BD's purpose to advance the world of health, providing researchers with innovative tools that drive a deeper understanding of the immune system and unlock its unique power to fight disease. We are pleased to select the Torrey View by Breakthrough campus to house this dynamic work now and in the future. The campus will accommodate a flexible working environment, support collaboration and innovation, and serve our desire to attract and retain the best talent for years to come." Torrey View is a 10-acre, world-class life sciences research and development campus that Breakthrough is creating alongside its co-equity partner Mitsui Fudosan America. Strategically located within San Diego's burgeoning Del Mar Heights life sciences cluster and adjacent to biopharma workforce housing, Torrey View will feature three research and development buildings and a tenant clubhouse. BD will lease the campus' largest planned building. At 220,000 square feet, BD Biosciences will occupy more than 40 percent of Torrey View's total available space. Daniel D'Orazi, Executive Vice President and Head of Acquisitions for Breakthrough Properties, added, "BD's early commitment to the project is emblematic of the intense and accelerating demand for high-quality research space in San Diego, which is benefitting from a continued influx of venture capital into the biopharma sphere. The Torrey View campus is the ideal office and lab solution to meet this need. We believe it will be a destination for innovative biotech and life sciences firms that will help them grow, expand, recruit top talent and establish a long-term presence in one of the top scientific research clusters in the nation." Steve Conly, Vice President and General Manager of BD Biosciences Research Solutions, said, "BD has enjoyed a longstanding presence in the San Diego region, with more than 4,000 BD associates currently located there, due to the area's vibrant business community and depth and breadth of talent. The location was selected after careful review of a number of alternatives and is a testament to our commitment to hiring and developing members of the San Diego community." In keeping with its commitment to providing customized and elevated customer experiences, Breakthrough's Torrey View campus will incorporate thoughtfully crafted indoor and outdoor communal spaces, as well as state-of-the-art conference and event facilities, all of which are meant to inspire interaction, collaboration and innovation. Torrey View will also include a full suite of curated tenant amenities, including multiple dining options, a Jay Wright-designed fitness center, pickleball courts, surfboard and bike storage, and onsite parking via a partially below-grade garage covered by open green spaces, gardens, and native plants. The best-in-class campus will also feature drought-tolerant landscaping, pedestrian and bicycle pathways, and a series of informal outdoor gathering areas to complement and enhance the surrounding community. "Tishman Speyer and Bellco Capital founded Breakthrough Properties because we recognized the intense demand for superior life sciences environments where companies like BD can explore, discover and grow," said Tishman Speyer Managing Director Paul De Martini. "We look forward to working with BD, the City of San Diego and the local community in producing a Torrey View campus that complements and enhances the surrounding Del Mar innovation district." Breakthrough acquired the Torrey View site in October 2020 and has designed it to LEED Gold standards. To realize its vision, Breakthrough is working with life science architectural firm FLAD Architects and general contractor Clark Construction. It has also retained Jones Lang LaSalle's (JLL) senior life science team in San Diego to help market and lease the space. To learn more about Torrey View, please visit www.torreyviewbybreakthrough.com . About Breakthrough Properties ( www.btprop.com ) Formed in 2019 as a joint venture between global real estate owner, developer and investor Tishman Speyer and biotechnology investment firm Bellco Capital, Breakthrough Properties is a life science real estate development company that leverages cross-sector collaboration to deliver environments that foster innovation and scientific breakthroughs. Breakthrough Properties' mission is to acquire, develop and operate the best life science properties in leading urban technology centers around the world and support scientific innovation across biotechnology, agriculture and nutrition. Breakthrough combines Tishman Speyer's decades of global real estate development experience with Bellco Capital's industry-making biotechnology entrepreneurship to reimagine environments where companies can create life-changing therapies for patients. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo . SOURCE Breakthrough Properties

Bd Biosciences Investments

1 Investments

Bd Biosciences has made 1 investments. Their latest investment was in Adaptive Biotechnologies as part of their Series F on May 5, 2015.

CBI Logo

Bd Biosciences Investments Activity

investments chart

Bd Biosciences Portfolio Exits

1 Portfolio Exit

Bd Biosciences has 1 portfolio exit. Their latest portfolio exit was Adaptive Biotechnologies on June 27, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/27/2019

IPO

$991

13

Date

6/27/2019

Exit

IPO

Companies

Valuation

$991

Acquirer

Sources

13

Bd Biosciences Acquisitions

1 Acquisition

Bd Biosciences acquired 1 company. Their latest acquisition was FlowJo on January 01, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/1/2017

Acquired

1

Date

1/1/2017

Investment Stage

Companies

Valuation

Total Funding

Note

Acquired

Sources

1

Bd Biosciences Partners & Customers

10 Partners and customers

Bd Biosciences has 10 strategic partners and customers. Bd Biosciences recently partnered with Analytical BioSciences on October 10, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

10/9/2020

Partner

Analytical BioSciences

China

3/26/2020

Partner

GlaxoSmithKline, Johnson & Johnson, Merck & Co., Merck KGaA, Novartis, Pfizer, Sanofi, Boehringer Ingelheim, bioMerieux, Eisai, Eli Lilly and Company, and Gilead Sciences

United Kingdom, United States, Germany, Switzerland, France, and Japan

Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic alongside Bill & Melinda Gates Foundation

Basel , March 26 , 2020 -- Today , Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development , manufacture and delivery of vaccines , diagnostics , and treatments for COVID-19 in response to the pandemic .

5

6/13/2017

Partner

FlowJo

United States

FlowJo and BD to Provide Cloud Platform for Real-Time Single-Cell Marketing Collaboration.

ASHLAND , Ore and FRANKLIN LAKES , N.J. , June 13 , 2017 ─ FlowJo , LLC , a life science informatics and data analysis company with 20 years of experience in software for analyzing single-cell data , and global medical technology company , BD , announced today that they have established a strategic relationship to catalyze the coordination of resources , people and data for the research market .

1

9/5/2013

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

6/13/2013

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

10/9/2020

3/26/2020

6/13/2017

9/5/2013

6/13/2013

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Analytical BioSciences

GlaxoSmithKline, Johnson & Johnson, Merck & Co., Merck KGaA, Novartis, Pfizer, Sanofi, Boehringer Ingelheim, bioMerieux, Eisai, Eli Lilly and Company, and Gilead Sciences

FlowJo

Country

China

United Kingdom, United States, Germany, Switzerland, France, and Japan

United States

Subscribe to see more

Subscribe to see more

News Snippet

Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic alongside Bill & Melinda Gates Foundation

Basel , March 26 , 2020 -- Today , Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development , manufacture and delivery of vaccines , diagnostics , and treatments for COVID-19 in response to the pandemic .

FlowJo and BD to Provide Cloud Platform for Real-Time Single-Cell Marketing Collaboration.

ASHLAND , Ore and FRANKLIN LAKES , N.J. , June 13 , 2017 ─ FlowJo , LLC , a life science informatics and data analysis company with 20 years of experience in software for analyzing single-cell data , and global medical technology company , BD , announced today that they have established a strategic relationship to catalyze the coordination of resources , people and data for the research market .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

1

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.